BLUE_OUT_1 [2025-03-31 09:54:19 -0400] 1967 Bytes | 558 tokens | Cum: 558 tkns (6.98% of 8k)
==========================================================================

We're scouting for winners today. Its 9:54:18 AM on Mon Mar 31, 2025 -0400 and I'm looking at bluebird bio (BLUE) up to 5 from 4.08

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

Here's the first list of news for bluebird bio:

C1 - Mar-28-25 04:15PM - bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
C2 - Mar-27-25 06:25PM - Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates
C3 - Mar-22-25 06:46AM - What Moved Markets This Week
C4 - Feb-21-25 01:22PM - Struggling bluebird bio to go private for less than $30m
C5 - Feb-21-25 01:22PM 08:53AM - What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
C6 - Feb-21-25 01:22PM 07:30AM - bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
C7 - Dec-29-24 06:07AM - bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?
C8 - Dec-08-24 12:30PM - bluebird bio Presents Positive Long-Term Data On LYFGENIA (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on bluebird bio (BLUE)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

BLUE_OUT_3 [2025-03-31 09:54:23 -0400] 517 Bytes | 159 tokens | Cum: 719 tkns (8.99% of 8k)
==========================================================================

Showing C1 (chunk 1 of 1): C1:
**bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid**
Date: Mar-28-25 04:15PM
Source: (Business Wire)
URL: https://www.businesswire.com/news/home/20250328122748/en

Error fetching article: 403 Client Error: Forbidden for url: https://www.businesswire.com/news/home/20250328122748/en

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BLUE_OUT_5 [2025-03-31 09:54:24 -0400] 908 Bytes | 254 tokens | Cum: 1069 tkns (13.36% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-29T02:52:22Z - Bluebird Bio confirms receipt non-binding proposal from Ayrmid...
A2 - 2025-03-28T20:48:06Z - Bluebird bio stock rises on new acquisition proposal By Investing.com...
A3 - 2025-03-28T21:05:46Z - 12 Health Care Stocks Moving In Friday's After-Market Session - bluebird bio (NASDAQ:BLUE), Biodesix...
A4 - 2025-03-28T20:48:06Z - Bluebird bio stock rises on new acquisition proposal By Investing.com...
A5 - 2025-03-28T20:48:06Z - Bluebird bio stock rises on new acquisition proposal By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

BLUE_OUT_7 [2025-03-31 09:54:29 -0400] 1098 Bytes | 286 tokens | Cum: 1357 tkns (16.96% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Bluebird Bio confirms receipt non-binding proposal from Ayrmid**Date: 2025-03-29Source: {'uri': 'markets.businessinsider.com', 'dataType': 'news', 'title': 'Markets Insider'}URL: https://markets.businessinsider.com/news/stocks/bluebird-bio-confirms-receipt-non-binding-proposal-from-ayrmid-1034527985bluebird bio (BLUE) confirmed it has received an unsolicited non-binding written proposal from Ayrmid Ltd to acquire bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone. As previously announced on February 21, 2025, bluebird entered into a definitive agreement with funds managed by global investment firms Carlyle and SK Capital Partners, LP to be acquired and taken private for $3.00 per share in cash and a one-time contingent value right of $6.84 per share payable upon achieveme

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BLUE_OUT_9 [2025-03-31 09:54:30 -0400] 998 Bytes | 304 tokens | Cum: 1785 tkns (22.31% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-11T14:17:35Z - Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
B2 - 2025-02-21T13:53:37Z - What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
B3 - 2025-02-11T11:48:00Z - EMV POS Terminal Global Strategic Business Report 2025: Market to Double to $20.6 Billion by 2030 - Focus on Compliance with EMV Standards, Advances in User Interface Propels Market Growth
B4 - 2024-12-26T12:18:00Z - Gene Therapy Market Analysis,Growth, Insights and Future Outlook | Exactitude Consultancy
B5 - 2024-12-22T17:25:00Z - This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?
B6 - 2024-10-26T10:32:00Z - The Ultimate Biotech Stock to Buy With $50 Right Now

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BLUE_OUT_11 [2025-03-31 09:54:33 -0400] 689 Bytes | 216 tokens | Cum: 2003 tkns (25.04% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/general/biotech/25/03/44249407/bristol-myers-squibb-scoops-up-its-blood-cancer-drug-partner-2seventy-bio-in-286-million-dealBristol Myers Squibb is acquiring 2seventy Bio, its blood cancer drug partner, for $286 million in an all-cash deal. The acquisition represents an 88% premium over 2seventy Bio's closing price.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BLUE_OUT_13 [2025-03-31 09:54:34 -0400] 806 Bytes | 216 tokens | Cum: 2274 tkns (28.43% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-27 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following is a discussion of the results of operations for our fiscal years ended December 31, 2024 and 2023, and changes in financial condition during those years. The following i...

S5 - 2025-02-21 8-K Item1.01 Entry Into a Material Definitive Agrmt.

Agrmt and Plan of Merger

On February 21, 2025, bluebird bio, Inc., a Delaware corporation (the Company or bluebird bio), entered into an Agrmt and Plan of Merger (the Merger Agrmt) with Beacon Parent Holdings, L...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BLUE_OUT_15 [2025-03-31 09:54:38 -0400] 1098 Bytes | 237 tokens | Cum: 2513 tkns (31.41% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

The following is a discussion of the results of operations for our fiscal years ended December 31, 2024 and 2023, and changes in financial condition during those years. The following information should be read in conjunction with the consolidated financial statements and related notes thereto included in this Annual Report on Form 10-K.

In addition to historical information, this report contains forward-looking statements that involve risks and uncertainties which may cause our actual results to differ materially from plans and results discussed in forward-looking statements. We encourage you to review the risks and uncertainties discussed in the sections entitled Item 1A. Risk Factors and Forward-Looking Statements included at the beginning of this Annual Report on Form 10-K. The risks a

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BLUE_OUT_17 [2025-03-31 09:54:48 -0400] 6328 Bytes | 1765 tokens | Cum: 4369 tkns (54.61% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+------------------------+-------------------------+-------------------------+
| Volume: 191,166 | Perf Month: 11.19% | Option/Short: Yes / Yes | Sales Y/Y TTM: 184.12% |
+---------------------+------------------------+-------------------------+-------------------------+
| Avg Volume: 359.32K | Perf Quarter: -48.33% | Short Float: 19.20% | ROE: -295.35% |
+---------------------+------------------------+-------------------------+-------------------------+
| Rel Volume: 7.40 | Index: RUT | Short Ratio: 5.15 | ROI: -174.66% |
+---------------------+------------------------+-------------------------+-------------------------+
| RSI (14): 52.59 | Market Cap: 44.19M | Short Interest: 1.85M | Sales Surprise: -41.21% |
+---------------------+------------------------+-------------------------+-------------------------+
| ATR (14): 0.36 | Shs Outstand: 9.73M | Beta: 0.52 | EPS Surprise: 14.87% |
+---------------------+------------------------+-------------------------+-------------------------+
| SMA20: 15.16% | Shs Float: 9.64M | Sales Q/Q: 391.72% | P/E: - |
+---------------------+------------------------+-------------------------+-------------------------+
| SMA50: -17.13% | Inst Own: 31.00% | Sales past 5Y: 160.48% | Earnings: Nov 14 BMO |
+---------------------+------------------------+-------------------------+-------------------------+
| SMA200: -58.97% | Insider Own: 1.08% | Employees: 248 | |
+---------------------+------------------------+-------------------------+-------------------------+
| Perf Week: 15.73% | Insider Trans: -28.66% | Debt/Eq: - | |
+---------------------+------------------------+-------------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: bluebird bio, Inc. (BLUE) by Obenshain Andrew (President and CEO) on 2025-03-03
- Common Stock: 921 shares at $3.9194 (D) Footnote: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.

Inside Trans: bluebird bio, Inc. (BLUE) by Klima Thomas J (See Remarks) on 2025-03-03
- Common Stock: 500 shares at $3.9194 (D) Footnote: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.

Inside Trans: bluebird bio, Inc. (BLUE) by Colvin Richard A (Chief Medical Officer) on 2025-03-03
- Common Stock: 584 shares at $3.9194 (D) Footnote: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.

Inside Trans: bluebird bio, Inc. (BLUE) by Obenshain Andrew (President and CEO) on 2025-02-10
- Common Stock: 763 shares at $0 (D)

Inside Trans: bluebird bio, Inc. (BLUE) by Obenshain Andrew (President and CEO) on 2025-02-03
- Common Stock: 86 shares at $7.3925 (D) Footnote: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.

Inside Trans: bluebird bio, Inc. (BLUE) by Vittiglio Joseph (Chief Business & Legal Officer) on 2025-02-03
- Common Stock: 238 shares at $7.3925 (D) Footnote: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.

Inside Trans: bluebird bio, Inc. (BLUE) by Colvin Richard A (Chief Medical Officer) on 2025-02-03
- Common Stock: 64 shares at $7.3925 (D) Footnote: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.

Inside Trans: bluebird bio, Inc. (BLUE) by Klima Thomas J (See Remarks) on 2025-02-03
- Common Stock: 122 shares at $7.3925 (D) Footnote: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 83807000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -240715000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 5.0103
Average Volume: 343909.14
30-Day High: 5.0103
30-Day Low: 3.73

[Detailed Financials: TTM 2024]
- Total Assets: $460,232,000.0
- Total Liabilities: $491,766,000.0
- Total Equity: $-31,534,000.0
- Current Assets: $154,668,000.0
- Current Liabilities: $321,462,000.0

[Income Statement: TTM 2024]
- Revenue: $83,807,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -24.84

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-168,654,000.0

[Detailed Financials: FY 2024]
- Total Assets: $460,232,000.0
- Total Liabilities: $491,766,000.0
- Total Equity: $-31,534,000.0
- Current Assets: $154,668,000.0
- Current Liabilities: $321,462,000.0

[Income Statement: FY 2024]
- Revenue: $83,807,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -24.84

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-168,654,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

BLUE_OUT_19 [2025-03-31 09:54:51 -0400] 676 Bytes | 167 tokens | Cum: 4783 tkns (59.79% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

BLUE_IN_21 [2025-03-31 09:54:52 -0400] 126 Bytes | 29 tokens | Cum: 4897 tkns (61.21% of 8k)
==========================================================================

====================================
[2025-03-31 09:54:52] # Analysis Completed
Elapsed Time: 33.48 seconds